アブストラクト
Japanese
| Title | COVID-19罹患後における肺機能検査指標の経時的変化と低下に関連する因子の検討 |
|---|---|
| Subtitle | 原著 |
| Authors | 濱野葵1), 鳥居裕太1), 宮川祥治1), 菅沼直生子1), 川井順一1) |
| Authors (kana) | |
| Organization | 1)神戸市立医療センター中央市民病院臨床検査技術部 |
| Journal | 医学検査 |
| Volume | 73 |
| Number | 1 |
| Page | 1-8 |
| Year/Month | 2024 / 1 |
| Article | 原著 |
| Publisher | 日本臨床衛生検査技師会 |
| Abstract | 「要旨」2019年以降世界的大流行をもたらしている新型コロナウイルス感染症 (COVID-19) は呼吸器系に多大な影響を及ぼし, 特に拘束性換気障害および肺拡散能低下をきたすと報告されている. しかし, 本邦における肺機能検査指標の検討についての報告はない. 本研究の目的はCOVID-19罹患後における肺機能検査指標の経時的変化および低下に関連する因子について検討することである. 対象はCOVID-19と診断され, 入院加療後に肺機能検査を施行した患者50例である. 対象患者は退院後3か月, 6か月, 9〜12か月後に肺機能検査を実施した. 患者背景では, 低下群においてCOVID-19の重症度が有意に高く, 入院日数が長く, 後遺症症状が多かった. 肺機能検査指標では, 低下群で退院後9〜12か月後の%全肺気量 (%TLC) は改善を認めるものの, 正常群と比較して実測値の低下を認め, 肺の線維化や炎症の残存が示唆された. また, 退院後3か月の肺機能検査指標を用いて検討した結果, 12か月後の肺機能指標の低下に最も関連する因子は%肺拡散能 (%DLco) であったが, その実測値は経時的な改善に乏しく, 長期にわたる肺機能障害への関与が示唆された. 今回の検討で低下群では持続する拘束性換気障害および肺拡散能の低下を認めた. また, 退院後3か月の%DLcoはCOVID-19罹患12か月後の肺機能検査指標の低下に関連する因子である. |
| Practice | 医療技術 |
| Keywords | 新型コロナウイルス, 肺機能検査, 肺拡散能, 拘束性換気障害, COVID-19肺炎, COVID-19, spirometry, DLco, restrictive lung diseases, COVID-19 pneumonia |
English
| Title | Investigation of changes in lung function test parameters following coronavirus disease (COVID-19) infection and associated factors |
|---|---|
| Subtitle | Original Article |
| Authors | Aoi HAMANO1), Yuta TORII1), Shoji MIYAGAWA1), Naoko SUGANUMA1), Junichi KAWAI1) |
| Authors (kana) | |
| Organization | 1)Department of Clinical Laboratory, Kobe City Medical Center General Hospital |
| Journal | Japanese Journal of Medical Technology |
| Volume | 73 |
| Number | 1 |
| Page | 1-8 |
| Year/Month | 2024 / 1 |
| Article | Original article |
| Publisher | Japanese Association of Medical Technologists |
| Abstract | [Summary] The novel coronavirus infection (COVID-19 : coronavirus disease 2019), which has caused a global pandemic since 2019, has been reported to have a significant impact on the respiratory system, particularly resulting in restricted ventilation impairment and decreased pulmonary diffusion capacity. However, there are no reports on lung function tests (LFTs) in Japan. In this study, we investigated changes in LFT results over time and normal factors after COVID-19 infection. LFTs were performed at 3, 6, and 9-12 months in 50 patients (33 in the normal group : forced vital capacity % predicted (%FVC) >= 80% and diffusing capacity of the lung for carbon monoxide % predicted (%DLco) >= 80% and 17 in the decreased group: %FVC < 80% or %DLco <80%) after discharge from the hospital. The results showed that the decreased group had higher severity, longer hospital stays, and more residual symptoms. Although the total lung capacity (TLC) was improved in the decreased group 9-12 months after treatment, the measured %TLC was lower than that in the normal group, indicating potential residual fibrosis or inflammation, which was caused by interstitial pneumonia. The factor most strongly associated with the decreased group was %DLco, but its longitudinal changes were limited. Diffusion impairment was speculated to persist for a long time and could be observed at 3 months after discharge, indicating its involvement in long-term lung dysfunction. The decreased group in this study demonstrated restrictive ventilation impairment and decreased lung diffusion capacity, indicative of long-term lung dysfunction. Furthermore, %DLco at 3 months after discharge was identified as a factor associated with normal or decreased LFT parameters following COVID-19 infection. |
| Practice | Medical technology |
| Keywords | COVID-19, spirometry, DLco, restrictive lung diseases, COVID-19 pneumonia |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) World Health Organization: WHO Coronavirus(COVID-19) Dashboard. http://covid19.who.int
- 2) Shi H et al.: Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis, 2020; 20: 425-434.
- 3) Namendys-Silva SA: ECMO for ARDS due to COVID-19. Heart Lung, 2020; 49: 348-349.
- 4) Wang F et al.: Long-term respiratory and neurological sequelae of COVID-19. Med Sci Monitor, 2020; 26: e928996.
- 5) Mo X et al.: Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J, 2020; 55: 2001217.
残りの11件を表示する
- 6) Torres-Castro R et al.: Respiratory function in patients post-infection by COVID-19: A systematic review and meta-analysis. Pulmonology, 2021; 27: 328-337.
- 7) Li X et al.: Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: A cohort study. Respir Res, 2021; 22: 203.
- 8) Bazdyrev E et al.: Lung fibrosis after COVID-19: Treatment prospects. Pharmaceuticals(Basel), 2021; 14: 807.
- 9) Wu X et al.: 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalization: A prospective study. Lancet Respir Med, 2021; 9: 747-754.
- 10) 厚生労働省 : 新型コロナウイルス感染症COVID-19診療の手引き 第9.0版. https://www.mhlw.go.jp/content/000936655.pdf
- 11) 日本呼吸器学会 肺生理専門委員会 呼吸機能検査ハンドブック作成委員会 : 第2章 肺拡散能. 呼吸機能検査ハンドブック, 24-31, (一社)日本呼吸器学会, メディカルレビュー社, 東京, 2021.
- 12) Bourgonje AR et al.: Sin-converting enzyme 2(ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019(COVID-19). J Pathol, 2020; 251: 228-248.
- 13) Tian S et al.: Pathological study of the 2019 novel coronavirus disease(COVID-19)through postmortem core biopsies. Mod Pathol, 2020; 33: 1007-1014.
- 14) Shao C et al.: Evolution of severe acute respiratory syndrome coronavirus 2 RNA test results in a patient with fatal coronavirus disease 2019: A case report. Hum Pathol, 2020; 101: 82-88.
- 15) Blanco JR et al.: Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clin Microbiol Infect, 2021; 27: 892-896.
- 16) Bellan M et al.: Long-term sequelae are highly preVAlent one year after hospitalization for severe COVID-19. Sci Rep, 2021; 11: 22666.
